“Advancements in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies”
- One prominent trend in next-generation bio-therapeutics is the increasing development of antibody-drug conjugates (ADCs) and bispecific antibodies, which provide targeted, potent treatments with reduced systemic toxicity
- These therapies combine the specificity of monoclonal antibodies with the potency of cytotoxic drugs, improving treatment efficacy in cancers and autoimmune diseases
- For instance, ADCs like Brentuximab Vedotin have shown high response rates in treating cancers such as Hodgkin lymphoma, transforming the landscape of cancer therapy with highly targeted treatments
- These advancements are driving the demand for novel therapies in oncology, autoimmune diseases, and other therapeutic areas, with new molecules entering clinical trials and approval pipelines
